Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | MITF | O75030 | 1/20 | 0.35 |
| ▸ | NSD2 | O96028 | 1/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.35 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.35 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6325005 | 0.69 | MAPT (0.44) | ALDH1A1KMT2AMAPTHSD17B10POLB | |
| SCHEMBL14505735 | 0.64 | ALDH1A1 (0.33) | ALDH1A1POLB | |
| SCHEMBL14505734 | 0.60 | ALDH1A1 (0.31) | ALDH1A1KMT2AMAPTHSD17B10 | |
| Mucochloric Acid SCHEMBL1010785 | 0.56 | — | — | |
| SCHEMBL10613045 | 0.56 | IDO1 (0.31) | — | |
| SCHEMBL414388 | 0.55 | KMT2A (0.35) | ALDH1A1KMT2AMAPTHSD17B10POLB | |
| SCHEMBL7109964 | 0.54 | DPP7 (0.37) | ALDH1A1KMT2A | |
| SCHEMBL1568044 | 0.52 | — | — | |
| SCHEMBL14505730 | 0.52 | KDM4E (0.40) | ALDH1A1KMT2AMAPTHSD17B10POLB | |
| SCHEMBL366613 | 0.52 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005026141-A2 | PROCESS FOR PREPARATION OF SUBSTITUTED BUTENOLIDES VIA PALLADIUM-FREE ETHERIFICATION AND AMINATION OF MASKED MUCOHALIC ACIDS | WARNER-LAMBERT COMPANY LLC (US) | 2005-03-24 | — | — | WO | claimed |
| WO-2005026141-A2 | PROCESS FOR PREPARATION OF SUBSTITUTED BUTENOLIDES VIA PALLADIUM-FREE ETHERIFICATION AND AMINATION OF MASKED MUCOHALIC ACIDS | WARNER-LAMBERT COMPANY LLC (US) | 2005-03-24 | — | — | WO | disclosed |
| US-20050059831-A1 | Preparation of substituted butenolides via palladium-free etherification and amination of masked mucohalic acids | BLAZECKA PETER GARTH (CA) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059831-A1 | Preparation of substituted butenolides via palladium-free etherification and amination of masked mucohalic acids | DBH, OR51E2, OR10J3 | ALDH1A1 161/4885KMT2A 902/4885MAPT 4622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.